Welcome to our dedicated page for Dynavax Technolo SEC filings (Ticker: DVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing feels like decoding immunology textbooks—especially when Dynavax packs vaccine science, CpG 1018 adjuvant data, and global supply contracts into hundreds of pages. Investors hunting for HEPLISAV-B revenue or R&D spend often ask, “Why can’t Dynavax’s 10-K just say it plainly?”
Stock Titan solves that problem. Our AI breaks down every Dynavax annual report 10-K simplified and each Dynavax quarterly earnings report 10-Q filing, highlighting where vaccine sales accelerate, how cash runway shifts, and what new trials mean for valuation. Need real-time alerts? We push Dynavax Form 4 insider transactions real-time so you can monitor Dynavax executive stock transactions Form 4 minutes after they hit EDGAR. We also tag every 8-K, giving you Dynavax 8-K material events explained—from FDA updates to BARDA awards—plus a clear view of Dynavax proxy statement executive compensation without wading through footnotes.
Whether you search for “Dynavax insider trading Form 4 transactions,” “Dynavax SEC filings explained simply,” or “understanding Dynavax SEC documents with AI,” you land on the same destination: concise bullet-point summaries, side-by-side financial comparisons, and AI-driven red-flag detection. Use our platform to dig into Dynavax earnings report filing analysis, track CpG 1018 supply economics, or set watchlists for trial milestone disclosures. With comprehensive coverage, instant updates, and approachable explanations, Stock Titan turns complex Dynavax filings into actionable knowledge.
Dynavax Technologies (DVAX) reported Q3 results with total revenue of $94.9 million, led by HEPLISAV-B product revenue of $90.0 million. Net income for the quarter was $26.9 million, up from $17.6 million a year ago, as higher product sales offset operating costs.
Year-to-date, revenue reached $258.5 million. Despite stronger sales, the company recorded a year-to-date net loss of $50.5 million, driven primarily by an $82.1 million loss on debt extinguishment related to a March 2025 refinancing of its convertible notes. Other revenue included $4.7 million in Q3 from the U.S. Department of Defense collaboration.
Liquidity remained solid. Cash and cash equivalents were $160.2 million and marketable securities were $487.6 million as of September 30, 2025. Total assets were $946.5 million and stockholders’ equity was $534.1 million. The company completed its $200 million share repurchase authorization, reducing common shares outstanding; as of November 3, 2025, there were 117,424,968 shares outstanding.
Dynavax refinanced a portion of its convertibles, issuing $225.0 million of 2.00% notes due 2030 and leaving $40.2 million of 2.50% notes due 2026 outstanding. Q3 diluted EPS was $0.21.
Dynavax Technologies Corporation furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025 and unveiling a new $100 million share repurchase program via an accompanying press release. The press release was furnished as Exhibit 99.1 and provides the detailed results and program terms.
This 8-K indicates the results and buyback authorization were communicated through a press release that is incorporated by reference for informational purposes, while the 8-K itself notes the information is furnished, not filed under the Exchange Act. Shares of DVAX continue to trade on the Nasdaq Global Select Market.
Dynavax Technologies Corporation announced leadership changes tied to an internal realignment. Effective January 1, 2026, David F. Novack will transition from President and Chief Operating Officer to Senior Vice President and Chief Operating Officer.
The Board approved the removal of Robert Janssen, M.D. from his roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier of the Company hiring a new Chief Medical Officer or March 2, 2026. Dr. Janssen’s employment will conclude as of March 2, 2026. The Company has commenced a search for a successor Chief Medical Officer.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and individual David Kroin report shared beneficial ownership of 15,726,349 shares of Dynavax Technologies Corporation common stock, representing 13.41% of the 117,267,482 shares outstanding cited in the filing. The filing is Amendment No. 2 to a prior Schedule 13G/13D series and states the Reporting Persons are eligible to report on Schedule 13G under Rule 13d-1(h), replacing the prior Schedule 13D disclosures.
The cover-page details show the Reporting Persons have no sole voting or dispositive power and only shared voting and dispositive power over the reported shares.
Dynavax Technologies director Scott Myers purchased 3,800 shares of Dynavax Technologies Corp (DVAX) on 08/22/2025 at $10.82 per share in an open-market transaction. After the purchase he beneficially owns 35,004 shares, reported as direct ownership. The Form 4 was filed by a single reporting person and signed on 08/25/2025 by an attorney-in-fact. The filing discloses only this non-derivative common stock purchase; no options, dispositions, or additional transactions are reported.
Dynavax Technologies (DVAX) insiders reported two open-market dispositions on Aug 21-22, 2025. Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and David Kroin (reported as director/10% owners) sold 1,094,994 shares on 08/21/2025 at $11.03 and 970,143 shares on 08/22/2025 at $10.59. After those transactions the Reporting Persons reported beneficial ownership of 16,696,492 shares following the first sale and 15,726,349 shares following the second sale; ownership is reported as indirect. The Form 4 is filed jointly by the three Reporting Persons and includes signed disclosures clarifying possible pecuniary interests and shared voting/disposition power.
FAQ
What is the current stock price of Dynavax Technolo (DVAX)?
What is the market cap of Dynavax Technolo (DVAX)?
